RATE OF MARROW ENGRAFTMENT DOES NOT APPEAR TO BE ADVERSELY AFFECTED BY EARLY MARROW INFUSION AFTER TOTAL-BODY IRRADIATION

被引:0
作者
TRICKETT, AE
VOWELS, MR
SHING, MMK
FORD, D
LAMPOTANG, R
机构
[1] PRINCE WALES CHILDRENS HOSP,DEPT HAEMATOL ONCOL,RANDWICK,NSW 2031,AUSTRALIA
[2] PRINCE WALES CHILDRENS HOSP,BONE MARROW TRANSPLANT LABS,RANDWICK,NSW,AUSTRALIA
[3] PRINCE WALES HOSP,DEPT HAEMATOL,RANDWICK,NSW,AUSTRALIA
[4] UNIV NEW S WALES,SYDNEY,NSW,AUSTRALIA
关键词
BONE MARROW TRANSPLANTATION; ENGRAFTMENT; MARROW-SPACE; TOTAL BODY IRRADIATION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone marrow transplantation (BMT) provides a means of increasing chemo-radiotherapy doses beyond the limits imposed by marrow toxicity. The time interval between myeloablative therapy and marrow infusion needs to be optimized to ensure prompt engraftment. It has been suggested that early marrow infusion after completion of total body irradiation (TBI) may be detrimental to rapid marrow reconstitution. Hence a retrospective analysis of 75 BMT patients was performed to document the rate of marrow engraftment following marrow infusion given immediately after TBI. Engraftment rates (time to absolute neutrophil count to greater than 0.5 x 10(9)/L) of patients receiving different conditioning regimens were compared. Results show similar engraftment rates in patients receiving bone marrow infusion 27.7 and 32.1 hours after completion of chemotherapy in autologous (20.5 days) and allogeneic (18.5 days) transplants respectively, or 2.9 and 2.0 hours after completion of TBI in autologous (20.1 days) and allogeneic (19.4 days) transplants respectively. These results are similar to those reported for delayed marrow infusion after TBI and would support that early marrow infusion after TBI does not adversely influence rate of engraftment. Thus it appears appropriate to give marrow immediately after completion of TBI.
引用
收藏
页码:382 / 384
页数:3
相关论文
共 20 条
[1]  
ATKINSON K, 1989, BONE MARROW TRANSPL, V4, P23
[2]  
BAUME D, 1988, B CANCER, V75, P361
[3]  
BRECHER G, 1988, EXP HEMATOL, V16, P627
[4]  
COCCIA PF, 1988, BLOOD, V71, P888
[5]  
DAVIS HP, 1988, BONE MARROW TRANSPL, V3, P349
[6]   CYCLOSPORINE AS PROPHYLAXIS FOR GRAFT-VERSUS-HOST DISEASE - A RANDOMIZED STUDY IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOBLASTIC LEUKEMIA [J].
DEEG, HJ ;
STORB, R ;
THOMAS, ED ;
FLOURNOY, N ;
KENNEDY, MS ;
BANAJI, M ;
APPELBAUM, FR ;
BENSINGER, WI ;
BUCKNER, CD ;
CLIFT, RA ;
DONEY, K ;
FEFER, A ;
MCGUFFIN, R ;
SANDERS, JE ;
SINGER, J ;
STEWART, P ;
SULLIVAN, KM ;
WITHERSPOON, RP .
BLOOD, 1985, 65 (06) :1325-1334
[7]  
EDER JP, 1986, CANCER RES, V46, P4496
[8]  
JACOBSON LO, 1951, J LAB CLIN MED, V37, P683
[9]  
KORBLING M, 1989, BLOOD, V74, P1898
[10]   TOTAL-BODY IRRADIATION IN BONE-MARROW TRANSPLANTATION - THE INFLUENCE OF FRACTIONATION AND DELAY OF MARROW INFUSION [J].
LICHTER, AS ;
TRACY, D ;
LAM, WC ;
ORDER, SE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1980, 6 (03) :301-309